Alia Zander
Research Subjects
Alia Zander has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Timothy Taxter
Tempus AI, Chicago, IL
3 shared publications Ailin Jin
Tempus AI Inc, Chicago, Illinois, USA
2 shared publicationsBen Terdich
Tempus AI Inc, Chicago, Illinois, USA
2 shared publicationsChithra Sangli
Tempus AI, Chicago, IL
2 shared publications- Ezra Eddy Wyssam Cohen
Moores Cancer Center at University of California San Diego, La Jolla, California
2 shared publications - Gayle E. Woloschak
Department of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, USA
2 shared publications
Latest Publications
- Open Access
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500197
Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection in Pancreatic Ductal Adenocarcinoma
PURPOSE: FOLFIRINOX (FFX) and gemcitabine + nab-paclitaxel (GnP) are the most commonly administered first-line (1L) regimens for advanced, nonresectable, pancreatic ductal adenocarcinoma (PDAC). In the absence of biomarkers to predict response, clinical covariates such as age and performance status are often used by clinicians to select optimal treatment regimens. Purity independent subtyping of tumors (PurIST) is a molecular subtyping algorithm that classifies tumors as classical or basal. The current study was designed to validate PurIST as a prognostic biomarker for patients receiving 1L FFX and as a predictive biomarker for patients more likely to benefit from FFX versus GnP. PATIENTS AND METHODS: This is a prospectively designed, retrospective study using a real-world data set of 931 patients with advanced PDAC, treated with either 1L FFX or GnP, and designed to demonstrate associations of PurIST subtypes with clinical outcomes. The primary end point was overall survival (OS) in classical versus basal patients treated with 1L FFX, while the secondary end point was OS in classical patients—with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1—to compare 1L FFX versus GnP. RESULTS: Within the cohort of patients receiving 1L FFX (n = 536), basal subtype patients had a median OS of 7 months compared with classical subtype patients with a median OS of 11.8 months (hazard ratio [HR], 1.86 [95% CI, 1.49 to 2.33]; P < .001). In an analysis restricted to patients with classical subtype and ECOG PS of 0 or 1 (n = 311), there was a 33% relative risk reduction of death in patients treated with FFX compared with GnP, adjusting for age and ECOG PS (HR, 0.67 [95% CI, 0.48 to 0.94]; P < .009), with no comparable risk reduction in basal patients (subtype-treatment interaction, P = .002). CONCLUSION: Patients with PDAC of the PurIST classical subtype showed a significant OS benefit when treated with FFX as 1L versus GnP.
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500197
Open AccessReal-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection in Pancreatic Ductal Adenocarcinoma
PURPOSE: FOLFIRINOX (FFX) and gemcitabine + nab-paclitaxel (GnP) are the most commonly administered first-line (1L) regimens for advanced, nonresectable, pancreatic ductal adenocarcinoma (PDAC). In the absence of biomarkers to predict response, clinical covariates such as age and performance status are often used by clinicians to select optimal treatment regimens. Purity independent subtyping of tumors (PurIST) is a molecular subtyping algorithm that classifies tumors as classical or basal. The current study was designed to validate PurIST as a prognostic biomarker for patients receiving 1L FFX and as a predictive biomarker for patients more likely to benefit from FFX versus GnP. PATIENTS AND METHODS: This is a prospectively designed, retrospective study using a real-world data set of 931 patients with advanced PDAC, treated with either 1L FFX or GnP, and designed to demonstrate associations of PurIST subtypes with clinical outcomes. The primary end point was overall survival (OS) in classical versus basal patients treated with 1L FFX, while the secondary end point was OS in classical patients—with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1—to compare 1L FFX versus GnP. RESULTS: Within the cohort of patients receiving 1L FFX (n = 536), basal subtype patients had a median OS of 7 months compared with classical subtype patients with a median OS of 11.8 months (hazard ratio [HR], 1.86 [95% CI, 1.49 to 2.33]; P < .001). In an analysis restricted to patients with classical subtype and ECOG PS of 0 or 1 (n = 311), there was a 33% relative risk reduction of death in patients treated with FFX compared with GnP, adjusting for age and ECOG PS (HR, 0.67 [95% CI, 0.48 to 0.94]; P < .009), with no comparable risk reduction in basal patients (subtype-treatment interaction, P = .002). CONCLUSION: Patients with PDAC of the PurIST classical subtype showed a significant OS benefit when treated with FFX as 1L versus GnP.
- Open Access
- 30 May 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (5) , e011363
Development and validation of the Immune Profile Score (IPS), a novel multiomic algorithmic assay for stratifying outcomes in a real-world cohort of patients with advanced solid cancer treated with immune checkpoint inhibitors
Background Immune checkpoint inhibitors (ICIs) have transformed the oncology treatment landscape. Despite substantial improvements for some patients, the majority do not benefit from ICIs, indicating a need for predictive biomarkers to better inform treatment decisions. Methods A de-identified pan-cancer cohort from the Tempus multimodal real-world database was used for the development and validation of the Immune Profile Score (IPS) algorithm leveraging Tempus xT (648 gene DNA panel) and xR (RNA sequencing) (N=1,707 development cohort; N=1,600 validation cohort). The cohort consisted of patients with advanced stage cancer with solid tumor carcinomas across 16 cancer types treated with any ICI-containing regimen as the first or second line of therapy. The IPS model was developed using a machine learning framework that includes tumor mutational burden (TMB) and 11 RNA-based biomarkers as features. Results IPS-High patients demonstrated significantly longer overall survival (OS) compared with IPS-Low patients (HR=0.45, 90% CI (0.40 to 0.52)). IPS was consistently prognostic in programmed death-ligand 1 (PD-L1) (positive/negative), TMB (High/Low), microsatellite status (microsatellite instability (MSI)-High), and regimen (ICI only/ICI+other) subgroups. Additionally, IPS remained significant in multivariable models controlling for TMB, MSI, and PD-L1, with IPS HRs of 0.49 (90% CI 0.42 to 0.56), 0.47 (90% CI 0.41 to 0.53), and 0.45 (90% CI 0.38 to 0.53), respectively. In an exploratory predictive utility analysis of the subset of patients (n=345) receiving first-line chemotherapy (CT) and second-line ICI, there was no significant effect of IPS for time to next treatment on CT in L1 (HR=1.06 (90% CI 0.88 to 1.29)). However, there was a significant effect of IPS for OS on ICI in L2 (HR=0.63 (90% CI 0.49 to 0.82)). A test of interaction was statistically significant (pConclusions Our results demonstrate that IPS is a generalizable multiomic biomarker that can be widely used clinically as a prognosticator of ICI-based regimens.
- 30 May 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (5) , e011363
Open AccessDevelopment and validation of the Immune Profile Score (IPS), a novel multiomic algorithmic assay for stratifying outcomes in a real-world cohort of patients with advanced solid cancer treated with immune checkpoint inhibitors
Background Immune checkpoint inhibitors (ICIs) have transformed the oncology treatment landscape. Despite substantial improvements for some patients, the majority do not benefit from ICIs, indicating a need for predictive biomarkers to better inform treatment decisions. Methods A de-identified pan-cancer cohort from the Tempus multimodal real-world database was used for the development and validation of the Immune Profile Score (IPS) algorithm leveraging Tempus xT (648 gene DNA panel) and xR (RNA sequencing) (N=1,707 development cohort; N=1,600 validation cohort). The cohort consisted of patients with advanced stage cancer with solid tumor carcinomas across 16 cancer types treated with any ICI-containing regimen as the first or second line of therapy. The IPS model was developed using a machine learning framework that includes tumor mutational burden (TMB) and 11 RNA-based biomarkers as features. Results IPS-High patients demonstrated significantly longer overall survival (OS) compared with IPS-Low patients (HR=0.45, 90% CI (0.40 to 0.52)). IPS was consistently prognostic in programmed death-ligand 1 (PD-L1) (positive/negative), TMB (High/Low), microsatellite status (microsatellite instability (MSI)-High), and regimen (ICI only/ICI+other) subgroups. Additionally, IPS remained significant in multivariable models controlling for TMB, MSI, and PD-L1, with IPS HRs of 0.49 (90% CI 0.42 to 0.56), 0.47 (90% CI 0.41 to 0.53), and 0.45 (90% CI 0.38 to 0.53), respectively. In an exploratory predictive utility analysis of the subset of patients (n=345) receiving first-line chemotherapy (CT) and second-line ICI, there was no significant effect of IPS for time to next treatment on CT in L1 (HR=1.06 (90% CI 0.88 to 1.29)). However, there was a significant effect of IPS for OS on ICI in L2 (HR=0.63 (90% CI 0.49 to 0.82)). A test of interaction was statistically significant (pConclusions Our results demonstrate that IPS is a generalizable multiomic biomarker that can be widely used clinically as a prognosticator of ICI-based regimens.
- Open Access
Development and validation of the Immune Profile Score (IPS), a novel multi-omic algorithmic assay for stratifying outcomes in a real-world cohort of advanced solid cancer patients treated with immune checkpoint inhibitors
Background: Immune checkpoint inhibitors (ICIs) have transformed the oncology treatment landscape. Despite substantial improvements for some patients, the majority do not benefit from ICIs, indicating a need for predictive biomarkers to better inform treatment decisions. Methods: A de-identified pan-cancer cohort from the Tempus multimodal real-world database was used for the development and validation of the Immune Profile Score (IPS) algorithm leveraging Tempus xT (648 gene DNA panel) and xR (RNAseq). The cohort consisted of advanced stage cancer patients treated with any ICI-containing regimen as the first or second line of therapy. The IPS model was developed utilizing a machine learning framework that includes tumor mutational burden (TMB) and 11 RNA-based biomarkers as features. Results: IPS-High patients demonstrated significantly longer overall survival (OS) compared to IPS-Low patients (HR=0.45, 90% CI [0.40-0.52]). IPS was consistently prognostic in PD-L1 (positive/negative), TMB (High/Low), microsatellite status (MSS/MSI-H), and regimen (ICI only/ICI + other) subgroups. Additionally, IPS remained significant in multivariable models controlling for TMB, MSI, and PD-L1, with IPS HRs of 0.49 [0.42-0.56], 0.47 [0.41-0.53], and 0.45 [0.38-0.53] respectively. In an exploratory predictive utility analysis of the subset of patients (n=345) receiving first-line (1L) chemotherapy (CT) and second-line (2L) ICI, there was no significant effect of IPS for time to next treatment on CT in L1 (HR=1.06 [0.85-1.33]). However, there was a significant effect of IPS for OS on ICI in L2 (HR=0.63 [0.46-0.86]). A test of interaction was statistically significant (pWhat is already known on this topic – Advancements of multi-omic profiling technology in research settings has demonstrated the potential value of novel immune biomarkers for forecasting response to ICI therapies. However, despite these advances there remains an unmet clinical need for implementation of more sensitive and generalizable biomarkers to better predict patient outcomes to ICI due to limited availability of clinical multi-omic testing and validation cohorts. What this study adds – Our results demonstrate that IPS is a generalizable multi-omic biomarker that can be widely utilized clinically as a prognosticator of ICI based regimens. Importantly, IPS-High may identify patients within subgroups (TMB-L, MSS, PD-L1 negative) who benefit from ICI beyond what is predicted by existing biomarkers. How this study might affect research, practice or policy – In the near term IPS results can support patient stratification across pan-solid tumor cohorts to help inform clinicians and researchers which patients are more likely to benefit from ICI based regimens. In the future IPS may support label expansion of ICIs into cancer types without current approvals, and also potentially improve patient selection to minimize over-treatment with ICI in patients unlikely to respond.
Open AccessDevelopment and validation of the Immune Profile Score (IPS), a novel multi-omic algorithmic assay for stratifying outcomes in a real-world cohort of advanced solid cancer patients treated with immune checkpoint inhibitors
Background: Immune checkpoint inhibitors (ICIs) have transformed the oncology treatment landscape. Despite substantial improvements for some patients, the majority do not benefit from ICIs, indicating a need for predictive biomarkers to better inform treatment decisions. Methods: A de-identified pan-cancer cohort from the Tempus multimodal real-world database was used for the development and validation of the Immune Profile Score (IPS) algorithm leveraging Tempus xT (648 gene DNA panel) and xR (RNAseq). The cohort consisted of advanced stage cancer patients treated with any ICI-containing regimen as the first or second line of therapy. The IPS model was developed utilizing a machine learning framework that includes tumor mutational burden (TMB) and 11 RNA-based biomarkers as features. Results: IPS-High patients demonstrated significantly longer overall survival (OS) compared to IPS-Low patients (HR=0.45, 90% CI [0.40-0.52]). IPS was consistently prognostic in PD-L1 (positive/negative), TMB (High/Low), microsatellite status (MSS/MSI-H), and regimen (ICI only/ICI + other) subgroups. Additionally, IPS remained significant in multivariable models controlling for TMB, MSI, and PD-L1, with IPS HRs of 0.49 [0.42-0.56], 0.47 [0.41-0.53], and 0.45 [0.38-0.53] respectively. In an exploratory predictive utility analysis of the subset of patients (n=345) receiving first-line (1L) chemotherapy (CT) and second-line (2L) ICI, there was no significant effect of IPS for time to next treatment on CT in L1 (HR=1.06 [0.85-1.33]). However, there was a significant effect of IPS for OS on ICI in L2 (HR=0.63 [0.46-0.86]). A test of interaction was statistically significant (pWhat is already known on this topic – Advancements of multi-omic profiling technology in research settings has demonstrated the potential value of novel immune biomarkers for forecasting response to ICI therapies. However, despite these advances there remains an unmet clinical need for implementation of more sensitive and generalizable biomarkers to better predict patient outcomes to ICI due to limited availability of clinical multi-omic testing and validation cohorts. What this study adds – Our results demonstrate that IPS is a generalizable multi-omic biomarker that can be widely utilized clinically as a prognosticator of ICI based regimens. Importantly, IPS-High may identify patients within subgroups (TMB-L, MSS, PD-L1 negative) who benefit from ICI beyond what is predicted by existing biomarkers. How this study might affect research, practice or policy – In the near term IPS results can support patient stratification across pan-solid tumor cohorts to help inform clinicians and researchers which patients are more likely to benefit from ICI based regimens. In the future IPS may support label expansion of ICIs into cancer types without current approvals, and also potentially improve patient selection to minimize over-treatment with ICI in patients unlikely to respond.
- Open Access
- 2 October 2019
- Published by Andover House Inc in Precision Nanomedicine
- Vol. 2 (4) , 393-438
Protein Binding Effects of Dopamine Coated Titanium Dioxide Shell Nanoparticles
Non-targeted nanoparticles are capable of entering cells, passing through different subcellular compartments and accumulating on their surface a protein corona that changes over time. In this study, we used metal oxide nanoparticles with iron-oxide core covered with titanium dioxide shell (Fe3O4@TiO2), with a single layer of covalently bound dopamine covering the nanoparticle surface. Mixing nanoparticles with cellular protein isolates showed that these nanoparticles can form complexes with numerous cellular proteins. The addition of non-toxic quantities of nano-particles to HeLa cell culture resulted in their non-specific uptake and accumulation of protein corona on nanoparticle surface. TfRC, Hsp90 and PARP were followed as representative protein components of nanoparticle corona; each protein bound to nanoparticles with different affinity. The presence of nanoparticles in cells also mildly modulated gene expression on the level of mRNA. In conclusion, cells exposed to non-targeted nanoparticles show subtle but numerous changes that are consistent from one experiment to another.
- 2 October 2019
- Published by Andover House Inc in Precision Nanomedicine
- Vol. 2 (4) , 393-438
Open AccessProtein Binding Effects of Dopamine Coated Titanium Dioxide Shell Nanoparticles
Non-targeted nanoparticles are capable of entering cells, passing through different subcellular compartments and accumulating on their surface a protein corona that changes over time. In this study, we used metal oxide nanoparticles with iron-oxide core covered with titanium dioxide shell (Fe3O4@TiO2), with a single layer of covalently bound dopamine covering the nanoparticle surface. Mixing nanoparticles with cellular protein isolates showed that these nanoparticles can form complexes with numerous cellular proteins. The addition of non-toxic quantities of nano-particles to HeLa cell culture resulted in their non-specific uptake and accumulation of protein corona on nanoparticle surface. TfRC, Hsp90 and PARP were followed as representative protein components of nanoparticle corona; each protein bound to nanoparticles with different affinity. The presence of nanoparticles in cells also mildly modulated gene expression on the level of mRNA. In conclusion, cells exposed to non-targeted nanoparticles show subtle but numerous changes that are consistent from one experiment to another.
- 15 February 2019
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 95 (10) , 1378-1389
Radiation databases and archives – examples and comparisons
Studies of ionizing radiation effects through the archiving of data began with standardizing medical treatments in the early 1900s shortly after the discovery of X-rays. Once the breadth of the delayed effects of ionizing radiation was recognized, the need for long-term follow up became apparent. There are now many human archives of data from nuclear disasters and accidents, occupational exposures, and medical procedures. Planned animal irradiation experiments began around the time of the Cold War and included a variety of doses, fractions, dose rates, and types of ionizing radiation. The goal of most of these studies was to supplement information coming from human data through carefully planned experimental conditions and immediate and uninterrupted data collection. This review aims to highlight major archives and databases that have shaped the field of radiation biology and provide a broad range of the types of datasets currently available. By preserving all of these data and tissue sets, radiation biologists can combine databases and conduct large-scale analyses of detailed existing data and perform new assays with cutting edge scientific approaches.
- 15 February 2019
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 95 (10) , 1378-1389
Radiation databases and archives – examples and comparisons
Studies of ionizing radiation effects through the archiving of data began with standardizing medical treatments in the early 1900s shortly after the discovery of X-rays. Once the breadth of the delayed effects of ionizing radiation was recognized, the need for long-term follow up became apparent. There are now many human archives of data from nuclear disasters and accidents, occupational exposures, and medical procedures. Planned animal irradiation experiments began around the time of the Cold War and included a variety of doses, fractions, dose rates, and types of ionizing radiation. The goal of most of these studies was to supplement information coming from human data through carefully planned experimental conditions and immediate and uninterrupted data collection. This review aims to highlight major archives and databases that have shaped the field of radiation biology and provide a broad range of the types of datasets currently available. By preserving all of these data and tissue sets, radiation biologists can combine databases and conduct large-scale analyses of detailed existing data and perform new assays with cutting edge scientific approaches.